CLDI Presents CLD-501 Data
Calidi Biotherapeutics presents new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.